Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.

@article{Ferrario2013ClinicalAE,
  title={Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.},
  author={Carlos Maria Ferrario and Sumeet S Panjabi and Paul Buzinec and Jason P Swindle},
  journal={Therapeutic advances in cardiovascular disease},
  year={2013},
  volume={7 1},
  pages={27-39}
}
OBJECTIVES Since treatment regimen type can influence adherence and other outcomes, this study examined adherence, cardiovascular events, and economic outcomes in patients with hypertension treated with fixed-dose combination (FDC) amlodipine/olmesartan (AML/OM), FDC AML/benazepril (AML/BEN), and loose-dose combination AML plus angiotensin II receptor blockers (LDC AML/ARBs). METHODS Commercial health plan enrollees aged at least 18 years with index claim(s) for AML/OM, AML/BEN, or LDC AML… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…